Welcome to our dedicated page for Xylem SEC filings (Ticker: XYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xylem Inc. (NYSE: XYL) is a Fortune 500 global water solutions company that reports its financial and operational information to the U.S. Securities and Exchange Commission. The XYL SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools that help explain the content and context of each document.
Among the key filings for Xylem are its Form 10-K annual reports, which typically include a comprehensive discussion of the business, risk factors, and financial statements, and Form 10-Q quarterly reports, which update investors on revenue, margins, cash flows, and segment performance. For example, Xylem’s third-quarter 2025 results were furnished to the SEC via a Form 8-K that referenced its earnings press release and discussed revenue from products and services, adjusted earnings per share, and adjusted EBITDA margin.
The company also files Form 8-K current reports to announce material events such as quarterly results, portfolio transactions, and other significant developments. Recent 8-K filings have covered financial results for quarters ended June 30 and September 30, 2025, with exhibits that include the full text of related press releases.
On this page, users can review Xylem’s historical and ongoing SEC submissions, including annual and quarterly reports, current reports, and other required documents. Stock Titan’s AI-generated summaries highlight important sections, clarify technical language, and point out items that may be relevant to investors, such as segment commentary, outlook statements, and references to restructuring or portfolio optimization.
In addition, the filings page can surface insider transaction reports (Form 4) and proxy-related disclosures when available, helping users monitor equity awards, share ownership changes, and governance matters. Real-time updates from EDGAR combined with AI analysis make it easier to navigate Xylem’s filings and understand how the company communicates its financial condition, risks, and strategic priorities to regulators and the market.
Xylem Inc. executive vice president of strategy Albert Cho reported a mix of equity awards and related tax withholdings. On March 2, 2026 he received non-qualified stock options for 3,713 shares at $128.98 per share and a restricted stock unit award of 1,042 common shares.
Footnotes show several performance-based stock units granted in prior years vested based on Total Shareholder Return, Adjusted EBITDA, Revenue and ESG performance, increasing his common stock holdings. Shares totaling 1,610, 295 and 371 were withheld at $128.98 per share to cover tax liabilities tied to these vestings and restricted stock units. After these transactions, Cho directly owned 16,588 shares of Xylem common stock.
Xylem Inc. Pres. & CEO Matthew Francis Pine reported multiple equity compensation changes. On March 2, 2026, he received a grant of 57,386 non-qualified stock options with an exercise price of $128.98, scheduled to vest in one-third increments on March 1, 2027, 2028 and 2029.
He also acquired 16,105 shares of common stock as awards, and on March 1, 2026 vested performance-based stock units delivered 5,243, 4,328, 2,943 and 2,152 shares tied respectively to Total Shareholder Return, Adjusted EBITDA, Revenue and ESG performance, plus additional shares from dividend reinvestment.
To cover tax liabilities from these vestings, the company withheld 4,927, 847 and 2,316 shares of common stock at $128.98 per share. After these transactions, Pine holds both directly owned shares and an indirect position through the Matthew F. Pine and Angeles Lopez Guerrero Living Trust.
Xylem Inc. executive Meredith Emmerich received new equity awards. On March 2, 2026, Emmerich was granted 5,739 non-qualified stock options with an exercise price of $128.98 per share and 1,610 shares of common stock as a restricted stock unit award.
Both the options and restricted stock units were granted under the Xylem 2011 Omnibus Incentive Plan and are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. The filing also notes additional common shares from dividend reinvestment.
Xylem Inc. executive Stacy Cozad, EVP & Chief Legal Officer, reported equity awards under the company’s incentive plan. She received 5,570 non-qualified stock options at an exercise price of $128.98 per share and 1,563 shares of common stock as a grant.
Both the options and the restricted stock units are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. Following these transactions, she directly holds 5,570 options and 2,303 shares of common stock.
Xylem Inc. executive Michael J. McGann reported a mix of equity grants, vesting, and tax-related share withholdings. He received 5,739 non-qualified stock options at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
McGann also acquired common stock upon vesting of performance-based stock units granted under the Xylem 2011 Omnibus Incentive Plan, tied to Total Shareholder Return (1,966 shares), Adjusted EBITDA (1,622 shares), Revenue (1,103 shares), and ESG performance (489 shares), plus a 1,610-share restricted stock unit award that vests in thirds on the same 2027–2029 dates. To cover tax liabilities from these vestings, the company withheld 2,073, 213, and 510 shares of common stock at $128.98 per share.
Xylem Inc. EVP & Chief Financial Officer William K. Grogan reported equity compensation grants and associated tax withholdings. On March 2, 2026, he was awarded a non-qualified stock option for 18,228 shares at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. He also received 5,116 restricted stock units under the same plan, vesting in one-third increments on those same dates. On March 1, 2026, performance-based stock units granted on March 1, 2023 vested upon achievement of Total Shareholder Return, Adjusted EBITDA and Revenue goals, resulting in acquisitions of 5,551, 4,583 and 3,117 shares of common stock, respectively, including additional shares from dividend reinvestment. To cover tax liabilities from these vestings and a prior restricted stock unit grant, 5,888 and 578 shares of common stock were withheld at $128.98 per share. After these transactions, Grogan directly owned 40,151 shares of Xylem common stock and 18,228 options.
Xylem Inc. executive Rodney Aulick reported equity compensation awards and related tax withholding. On March 2, 2026, he received 5,739 non-qualified stock options with an exercise price of $128.98 and 1,610 restricted stock units under the Xylem 2011 Omnibus Incentive Plan.
The new options and RSUs are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. The filing also shows a disposition of 238 shares of common stock at $128.98 solely to cover tax liabilities from prior RSU vesting, leaving Aulick with 73,917 common shares held directly.
Xylem Inc. EVP and CPSO Claudia S. Toussaint reported equity compensation grants and related tax withholdings. On March 2, 2026, she received 7,089 non-qualified stock options with an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
She also acquired multiple blocks of common stock upon vesting of performance-based and ESG-related stock units granted in 2021 and 2023 under the Xylem 2011 Omnibus Incentive Plan, and received an additional restricted stock unit award set to vest in three annual tranches beginning March 1, 2027. To cover tax liabilities from these vestings, she disposed of several small blocks of common stock through share withholding at $128.98 per share. Following these transactions, she directly owns 9,342 shares of common stock, and an additional 31,250 shares are held indirectly by the Claudia S. Toussaint Revocable Trust.
Xylem Inc. executive Hayati Yarkadas reported equity awards and related tax withholdings. On March 1 and 2, 2026, he acquired several blocks of Xylem common stock through the vesting of performance-based and other stock units under the Xylem 2011 Omnibus Incentive Plan tied to metrics such as Total Shareholder Return, Adjusted EBITDA, Revenue, and ESG performance.
He also received an award of 8,102 non-qualified stock options at an exercise price of $128.98 per share and an additional award of 2,274 restricted stock units scheduled to vest in three equal installments in 2027, 2028, and 2029. To cover tax liabilities from these vestings, a total of 776 shares of common stock were disposed of through tax-withholding transactions at $128.98 per share. After these transactions, he directly held 33,698 shares of common stock and 8,102 stock options.
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported several equity compensation transactions. She received a grant of 2,194 non-qualified stock options with a price of $128.98 per share, scheduled to vest in three annual installments beginning March 1, 2027.
On March 1, 2026, she acquired 721, 595, 405 and 489 shares of common stock upon vesting of performance-based and ESG-related stock units granted under the Xylem 2011 Omnibus Incentive Plan, reflecting achievement of performance goals tied to total shareholder return, adjusted EBITDA, revenue and ESG performance. She also received an award of restricted stock units scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
Related to these vestings, 654, 188 and 150 shares of common stock were withheld at $128.98 per share to cover tax liabilities, reducing her directly held common stock to 4,791 shares after the transactions.